Table 2 Surgery summary

From: Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Variables

Cam+nab-TP (n = 114)

Cam+TP (n = 116)

TP (n = 103)

Esophagectomy rate (%)a

86.4 (114/132)

89.2 (116/130)

79.8 (103/129)

Types of surgical procedures, n (%)

 McKeown

107 (93.9)

106 (91.4)

95 (92.2)

 Ivor-Lewis

6 (5.3)

10 (8.6)

7 (6.8)

 Sweet

1 (0.9)

0

0

 Other

0

0

1 (1.0)

Margin status, n (%)

 R0

113 (99.1)

111 (95.7)

95 (92.2)

 R1

1 (0.9)

4 (3.4)

6 (5.8)

 R2

0

1 (0.9)

2 (1.9)

Number of lymph nodes harvested

 Median (IQR)

34 (24–50)

37 (27–48)

32 (27–45)

Time from last neoadjuvant treatment to surgery (weeks)

 Median (IQR)

5.9 (5.0–7.1)

5.7 (5.0–7.4)

5.4 (4.9–6.3)

Duration of surgery (hours)

 Median (range)

4.3 (2.6–8.9)

4.2 (2.8–7.2)

4.2 (2.9–10.8)

Reoperations, n (%)b

0

1 (0.9)

1 (1.0)

Mortality within 30 days, n (%)c

1 (0.9)

2 (1.7)

1 (1.0)

Mortality within 90 days, n (%)d

2 (1.8)

2 (1.7)

1 (1.0)

  1. aBased on ITT population.
  2. bTwo patients underwent reoperation for adhesive intestinal obstruction (Cam+TP group) or anastomotic leak (TP group).
  3. cMortality within 30 days included sudden postoperative death, cause unknown (Cam+nab-TP group), septic shock (Cam+TP group) and myocardial infarction (TP group).
  4. dMortality within 90 days included mortality within 30 days, with one more death in Cam+nab-TP group (severe pneumonia).
Back to article page